Funding to support Phase 3 ENHANCE clinical program in COPD THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 (“MAR”). UPON PUBLICATION OF THIS ANNOUNCEMENT THIS INFORMATION IS NOW CONSIDERED IN THE PUBLIC DOMAIN.
We are focused on treating respiratory diseases with significant unmet medical needs, such as COPD, COVID-19, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker.
The condition causes loss of lung function, hospitalizations and death. COPD affects approximately 384 million people worldwide. It is the third leading cause of death globally, according to the World Health Organization.Find out more
March 1 2021